PNPLA4

Across TCGA pan-cancer cohorts, PNPLA4 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PNPLA4 data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PNPLA4 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PNPLA4 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where PNPLA4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	III,IV	0.849	0.380	.018	14	view →
LUAD	OS	Quartile	III,IV	1.000	0.427	.040	3	view →
CCRCC	OS	Quartile	II,III,IV	1.000	0.271	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PNPLA4–PDAC (OS)

Open the PDAC breakdown →